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We have demonstrated previously that the EGFR (epidermal
growth factor receptor) is a calmodulin (CaM)-binding protein.
To establish whether or not the related receptor ErbB2/Neu/HER2
also binds CaM, we used human breast adenocarcinoma SK-BR-3
cells, because these cells overexpress this receptor thus facili-
tating the detection of this interaction. In the present paper, we
show that ErbB2 could be pulled-down using CaM–agarose beads
in a Ca2+-dependent manner, as detected by Western blot analysis
using an anti-ErbB2 antibody. ErbB2 was also isolated by Ca2+-
dependent CaM-affinity chromatography. We also demonstrate
using an overlay technique with biotinylated CaM that CaM binds
directly to the immunoprecipitated ErbB2. The binding of bio-
tinylated CaM to ErbB2 depends strictly on the presence of Ca2+,
since it was prevented by the presence of EGTA. Moreover, the ad-
dition of an excess of free CaM prevents the binding of its bio-
tinylated form, demonstrating that this was a specific process.
We excluded any interference with the EGFR, as SK-BR-3 cells
express considerably lower levels of this receptor, and no de-
tectable EGFR signal was observed by Western blot analysis in
the immunoprecipitated ErbB2 preparations used to perform the
overlay assays with biotinylated CaM. We also demonstrate
that treating living cells with W7 [N-(6-aminohexyl)-5-chloro-
1-naphthalenesulphonamide], a cell-permeant CaM antagonist,
down-regulates ErbB2 phosphorylation, and show that W7 does
not interfere non-specifically with the activity of ErbB tyrosine
kinases. We also show that W7 inhibits the phosphorylation (activ-
ation) of both ERK1/2 (extracellular-signal-regulated kinases 1
and 2) and Akt/PKB (protein kinase B), in accordance with the
inhibition observed in ErbB2 phosphorylation. In contrast, W7
treatment increased the phosphorylation (activation) of CREB
(cAMP-response-element-binding protein) and ATF1 (activating
transcription factor-1), two Ca2+-sensitive transcription factors
that operate downstream of these ErbB2 signalling pathways,
most likely because of the absence of calcineurin activity. We
conclude that ErbB2 is a new CaM-binding protein, and that CaM
plays a role in the regulation of this receptor and its downstream
signalling pathways in vivo.
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INTRODUCTION
The ErbB2/Neu receptor, also named HER2, belongs to the EGFR
(epidermal growth factor receptor)/ErbB1/HER1 tyrosine kinase
subfamily, also formed by two additional members, ErbB3/HER3
and ErbB4/HER4 receptors [1,2]. ErbB2 plays an important role
in the development of certain human cancers, particularly because
it is overexpressed in adenocarcinomas of mammary and ovarian
origin, among others [3,4]. Ligand-induced heterodimerization of
ErbB2 with other members of the EGFR family appears to be the
underlying mechanism for its activation, as a specific physiolo-
gical soluble ligand for ErbB2 has not yet been identified. Thus
heregulins induce the heterodimerization of ErbB2 with either
ErbB3 or ErbB4, while EGF (epidermal growth factor) intervenes
in the heterodimerization of ErbB2 with EGFR [5,6].
An early signal generated by the activation of the EGFR is a
transient increase in [Ca2+]cyt (cytosolic concentration of free cal-
cium) (see [7] for a review). This Ca2+ signal is also generated
by EGFR–ErbB2 heterodimers, playing an important role in cell
motility in this case because of the involvement in cytoskeletal
reorganization [8]. Interestingly, the oscillations in [Ca2+]cyt
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generated by EGFR homodimers and EGFR–ErbB2 heterodimers
present different patterns [9]. The calcium signal generated by
ErbB receptors may have important functional implications, as
the ubiquitous Ca2+-sensor calmodulin (CaM) becomes activated
[10], and the Ca2+–CaM complex has been proposed to exert a
regulatory action on these receptors [7,11].
In this context, we have demonstrated previously that the EGFR
is a CaM-binding protein [12–16]. Although CaM is known to in-
activate the EGFR via phosphorylation mediated by CaM-depen-
dent protein kinase II (CaMK-II) [17–19], we have demonstrated
that CaM also exerts a direct inhibitory action on the tyrosine
kinase activity of the EGFR without the participation of this
serine/threonine kinase [12,13]. It was also demonstrated that
CaM binds directly to the EGFR in vitro [12,13,15] and in
living cells [16], and that the CaM-binding domain (CaM-BD)
of this receptor is located in its cytosolic juxtamembrane region
[14,16,20]. Moreover, a reciprocal competitive interplay between
CaM binding at this site and phosphorylation by protein kinase C
of Thr654, also located in this segment, was demonstrated [14].
The CaM-BD of the EGFR is highly conserved among mam-
malian species, and presents high homology with similar regions
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in other ErbB receptors, including ErbB2 [11,14]. Therefore it is
likely that CaM could interact with other members of the ErbB
family. In the present paper, we demonstrate that ErbB2 is in-
deed a CaM-binding protein, and that CaM plays a role in the regu-
lation of this receptor, and several ErbB2-initiated downstream
signalling pathways, in intact cells.
EXPERIMENTAL
Reagents
Polyclonal anti-ErbB2 antibody (C-18) developed in rabbit
against the C-terminus of the human receptor, mouse monoclonal
anti-phospho-ERK (extracellular-signal-regulated kinase) anti-
body (E-4) against phosphorylated Tyr204 of human ERK1/2,
rabbit polyclonal anti-Akt1/2 antibody (H-136) against a recombi-
nant protein corresponding to amino acids 345–480 of human
Akt1, rabbit polyclonal anti-phospho-CREB (cAMP-response-
element-binding protein) 1 antibody (Ser-133) [recognizing phos-
phorylated Ser133 of human CREB1, phosphorylated ATF1
(activating transcription factor-1)], rabbit polyclonal anti-CREB1
antibody (C-21) against a peptide mapping the C-terminus of hu-
man CREB1, mouse monoclonal anti-phospho-JNK (c-Jun N-ter-
minal kinase) antibody (G-7) (against a peptide corresponding to
human JNK1 containing phosphorylated Thr183 and Tyr185) and
polyclonal rabbit anti-JNK1 antibody (C-17) (against a peptide
mapping at the C-terminus of human JNK1) were from Santa Cruz
Biotechnology. Monoclonal anti-EGFR antibody from clone 13
(recognizing the intracellular segment 996–1022 of the human
receptor) developed in mouse, monoclonal anti-phosphotyrosine
RC20 antibody conjugated to horseradish peroxidase and mouse
monoclonal anti-NFAT1 antibody were obtained from BD Trans-
duction Laboratories. Anti-phosphotyrosine 4G10 antibody was
purchased from Upstate Biotechnology. Rabbit polyclonal anti-
phospho-Akt (Thr308) antibody and rabbit polyclonal anti-ERK1/2
antibody were purchased from Cell Signaling Technology. Rabbit
polyclonal anti-[phospho-p38 MAPK (mitogen-activated protein
kinase)] antibody (against a peptide containing phosphorylated
Thr180 and Tyr182 of human p38 MAPK) and rabbit polyclonal anti-
(p38 MAPK) (against a peptide corresponding to residues 341–
360 of human p38 MAPK) were purchased from Calbiochem.
Anti-rabbit IgG (heavy and light chains) developed in goat and
conjugated to horseradish peroxidase was purchased from Zymed
Laboratories. Anti-mouse IgG (Fc-specific) developed in goat
and conjugated to horseradish peroxidase, human recombinant
HRGβ1 (heregulin-β1), CaM–agarose, deoxycholic acid (sodium
salt), sodium orthovanadate, leupeptin, pepstatin A, aprotinin,
PMSF, poly(L-Glu/L-Tyr) (co-polymer of L-glutamic acid and
L-tyrosine; 4:1 stochiometric ratio) (20–50 kDa) and mouse
monoclonal anti-α-tubulin antibody (clone DM 1A) were pur-
chased from Sigma. CompleteTM mini EDTA-free protease inhibi-
tor tablets were obtained from Roche. Human EGF was obtained
from PeproTech EC (London, U.K.), and pre-stained molecular
mass standards for electrophoresis were from Bio-Rad. EZ-
linkTM NHS-LC-biotin and streptavidin conjugated to horseradish
peroxidase were from Pierce. BioTraceTM PVDF membranes were
purchased from Pall Gelman Laboratory (Mississauga, Ontario,
Canada), and OptiPhase HiSafe 2 scintillation fluid was from
Wallac. The ECL® (enhanced chemiluminescence) assay kit,
[methyl-3H]thymidine (46 Ci/mmol) and [γ -32P]ATP (triethylam-
monium salt) (3000 Ci/mmol) were from Amersham Biosciences.
Escherichia coli cultures expressing recombinant rat CaM [21]
were a gift from Professor Nobuhiro Hayashi from Fujita Health
University, Aichi, Japan. Other chemicals used in this work were
of analytical grade.
Cell cultures
Human breast adenocarcinoma SK-BR-3 cells (A.T.C.C.,
Manassas, VA, U.S.A.) and human epidermoid carcinoma
A431 cells were grown in DMEM (Dulbecco’s modified Eagle’s
medium) supplemented with 10% (v/v) FBS (foetal bovine
serum), 2 mM L-glutamine and 40 µg/ml gentamicin in a humi-
dified atmosphere of 5% (v/v) CO2 in air at 37 ◦C. The cells were
maintained overnight in a FBS-free medium before performing
the experiments.
[methyl-3H]Thymidine incorporation
Incorporation of [methyl-3H]thymidine into DNA was carried out
in confluent cell cultures essentially as described in [22]. Cells
grown to confluence in 24-well culture dishes and deprived of FBS
overnight were washed twice with 130 mM NaCl, 2.7 mM KCl
and 11.5 mM sodium/potassium phosphate (pH 7.4) (PBS) and
incubated for 14–16 h in 0.5 ml of DMEM supplemented with
1.2 µM (2 µCi/ml) [methyl-3H]thymidine in the absence or pre-
sence of 10% (v/v) FBS and concentrations of EGF or HRGβ1
as indicated in the legends of the Figures. Thereafter, cells were
treated with ice-cold 10% (w/v) trichloroacetic acid for 10 min,
solubilized with 0.2 M NaOH for 24 h, and neutralized with
0.2 M HCl. The radioactivity incorporated into the acid-insoluble
material was measured using a scintillation counter.
Purification of recombinant CaM and preparation
of biotinylated CaM
Recombinant rat CaM was purified from E. coli essentially as
described in [21], except that the soluble cell extract was heated
at 95 ◦C for 5 min before the heat-resistant proteins of the super-
natant were subjected to phenyl-Sepharose chromatography. The
concentration of CaM was determined spectrophotometrically at
276 nm using a molar absorption coefficient of 3740 M−1 · cm−1
[23]. Purified CaM was biotinylated using EZ-linkTM NHS-LC-
biotin as described in [24].
ErbB2 immunoprecipitation
Serum-starved confluent SK-BR-3 cells grown in dishes 15 cm in
diameter were incubated in the absence and presence of 10 nM
EGF or 100 ng/ml HRGβ1 for 2–5 min at room temperature (20–
22 ◦C). Thereafter, the medium was removed and 1 ml of a me-
dium containing 50 mM Tris/HCl (pH 8), 150 mM NaCl, 1 mM
EGTA, 1% (w/v) Triton X-100, 0.5% (w/v) deoxycholic acid,
1 mM sodium orthovanadate, 1 mM PMSF, 10 µg/ml leupeptin,
10 µg/ml pepstatin A and 10 µg/ml aprotinin (lysis buffer) was
added and incubation was continued for 30 min on ice. The cell
extract was collected by centrifugation at 15 600 g for 35 min, and
2–3 mg of solubilized proteins were incubated overnight with
4 µg of anti-ErbB2 antibody pre-coupled to 30 µl of a slurry
of Protein A–agarose in 200 µl of a medium containing 50 mM
Tris/HCl (pH 8), 150 mM NaCl, 1 mM sodium orthovanadate,
1 mM PMSF (TNOP buffer). The beads were collected by centri-
fugation at 3600 g for 40 s and washed six times in TNOP buffer.
The samples were boiled for 5 min in Laemmli sample buffer, the
beads were removed by centrifugation at 3600 g for 40 s, and
the supernatant was processed by SDS/PAGE as described below.
ErbB2 pull-down with CaM–agarose
Serum-starved confluent SK-BR-3 cells were solubilized using
the lysis buffer, the sample was centrifuged at 15 600 g for 1 h at
4 ◦C, and 1 mM CaCl2 was added. The sample (1 ml) was incu-
bated with a slurry of 30 µl of CaM–agarose equilibrated in a
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buffer containing 20 mM Hepes/NaOH (pH 7.5), 150 mM NaCl,
0.2 mM CaCl2 and 1 mM PMSF (Ca2+ buffer). Controls in the
presence of 1 mM EGTA instead of CaCl2 were also performed
(EGTA buffer). The CaM–agarose beads were washed six times
with the Ca2+ buffer or with the EGTA buffer, as required, col-
lecting the beads by centrifugation at 3600 g for 40 s. The material
bound to the beads was separated by boiling for 5 min in Laemmli
sample buffer, the beads were removed by centrifugation at 3600 g
for 40 s, and the supernatant was subjected to SDS/PAGE and
Western blot analysis as described below using an anti-ErbB2
antibody.
Isolation of ErbB2 by Ca2+-dependent CaM-affinity chromatography
A Triton X-100-solubilized cell extract from SK-BR-3 cells
was processed through a 3 ml CaM-agarose column equilibrated
with a buffer containing 25 mM Hepes/NaOH (pH 7.5), 135 mM
NaCl and 0.2 mM CaCl2 (Ca2+ buffer). After an extensive wash
(100 ml) with the Ca2+ buffer, CaM-binding proteins were eluted
(1 ml fractions) with a similar buffer containing 2 mM EGTA
instead of CaCl2 (EGTA buffer). Proteins in pooled fractions
(10 ml) were precipitated with 10% (w/v) trichloroacetic acid,
and subjected to SDS/PAGE and Western blot analysis as des-
cribed below using an anti-ErbB2 antibody.
CaM overlay experiments
The whole cell extract or the immunoprecipitated ErbB2 receptor
from SK-BR-3 cells from non-stimulated cultures, or from cultures
treated with 10 nM EGF for 1 min, were prepared as described
above, and subjected to SDS/PAGE as described below. The pro-
teins were electrotransferred on to a PVDF membrane using a
medium containing 48 mM Tris-base, 36.6 mM glycine, 20%
(v/v) methanol and 0.04% (w/v) SDS (TGMS medium), and
fixed with 0.2% (v/v) glutaraldehyde for 45 min in a medium
containing 0.1% (w/v) Tween 20, 100 mM Tris/HCl (pH 8.8),
500 mM NaCl and 0.25 mM KCl (T-TBS medium). The PVDF
membrane was blocked with 5% (w/v) BSA in T-TBS medium,
and incubated with 0.45 µg/ml biotinylated CaM in the presence
of 0.2 mM CaCl2 for 30 min at 37 ◦C, or overnight at 4 ◦C. Con-
trols containing 1 mM EGTA instead of CaCl2 were also per-
formed. After extensively washing the PVDF membrane in T-TBS
medium, streptavidin conjugated to horseradish peroxidase at a
1/3000 dilution was added and incubated for 30 min at 37 ◦C or
for 1 h at room temperature. The positive bands were developed
using the ECL® method, following the manufacturer’s instruc-
tions.
Western blot analysis
Serum-starved confluent SK-BR-3 or A431 cells grown in dishes
15 cm in diameter were incubated in the absence and presence of
10 nM EGF or 100 ng/ml HRGβ1 for 1 min at room temperature,
and the whole cell extracts were processed by SDS/PAGE as in-
dicated below. Proteins in the gel were electrotransferred on to a
PVDF membrane in TGMS medium, and the proteins were fixed
with 0.2% (v/v) glutaraldehyde for 45 min in T-TBS medium.
The PVDF membrane was blocked with 5% (w/v) BSA or 10%
(w/v) fat-free dried milk in T-TBS medium, and probed with the
RC20 anti-phosphotyrosine antibody conjugated to horseradish
peroxidase (1/2000 dilution), or alternatively with the 4G10 anti-
phosphotyrosine antibody (1/2000 dilution), and an appropriate
secondary antibody coupled to horseradish peroxidase (1/
3000 dilution). The PVDF membrane was reprobed with the
anti-EGFR antibody (1/2500 dilution) or the anti-ErbB2 antibody
(1/1000 dilution) after stripping the membrane in a medium
containing 100 mM 2-mercapthoethanol, 2% (w/v) SDS and
62.5 mM Tris/HCl (pH 6.7) at 50 ◦C for 30 min, or after overnight
incubation at room temperature. The activation status of dif-
ferent signalling pathways in SK-BR-3 cells incubated in the
absence and presence of 10 nM HRGβ1 was determined in whole
cell extracts by probing the PVDF membranes with the following
antibodies (1/1000 dilution): anti-phospho-ERK, anti-phospho-
Akt/PKB (protein kinase B), anti-(phospho-p38 MAPK), anti-
phospho-JNK and anti-phospho-CREB/phospho-ATF1. Appro-
priate secondary antibodies coupled to horseradish peroxidase at
a 1/3000 dilution were used as required. The positive bands were
developed using the ECL® method following the manufacturer’s
instructions. Adequate loading was ascertained by Fast Green
FCF protein staining of the PVDF membranes, or, alternatively, by
stripping and reproving the membranes with any of the following
antibodies(1/1000 dilution):anti-ErbB2,anti-α-tubulin,anti-ERK,
anti-Akt/PKB, anti-(p38 MAPK), anti-JNK and anti-CREB.
Preparation of solubilized membrane fractions
Cells were washed twice with PBS and broken by six forced
passages through a 25 G 5/8 needle in a buffer containing 50 mM
Hepes/NaOH (pH 7.4), 150 mM NaCl, 10 mM EDTA, 2 mM so-
dium orthovanadate, and a cocktail of protease inhibitors (1 tablet
for 10 ml) (buffer A). The sample was centrifuged at 600 g for
5 min, the pellet was discarded, the supernatant was resuspended
in buffer A, and centrifuged at 160 000 g for 1 h at 4 ◦C. The
new pellet was collected and solubilized in buffer A containing
1% (w/v) Triton X-100 on ice for 45 min, centrifuged again at
160 000 g for 1 h at 4 ◦C and the supernatant, denoted solubilized
membrane fraction, was collected.
Isolation of EGFR and tyrosine kinase assay
In order to test possible non-specific interfering effects of W7
[N -(6-aminohexyl)-5-chloro-1-naphthalenesulphonamide] on
ErbB receptor tyrosine kinase activity, rat liver EGFR was isolated
by Ca2+-dependent CaM-affinity chromatography as described
previously [12], and its auto(trans)phosphorylation and tyrosine
kinase activity toward an exogenous substrate was assayed in the
absence and presence of the CaM antagonist (15 µg/ml) using
poly(L-Glu/L-Tyr), following described protocols [12].
Other analytical procedures
Slab gel electrophoreses were performed according to Laemmli
[25] at 12 mA overnight in a 5–20% (w/v) linear gradient
polyacrylamide gel in the presence of 0.1% (w/v) SDS at
pH 8.3. Protein concentrations were determined using BCA
(bicinchoninic acid; Sigma) and copper sulphate (BCA method)
following the manufacturer’s instructions and using BSA as a
standard. Densitometric measurement of the different bands in the
X-ray films were performed by a computer-assisted densitometer
(Epson Perfection 1200U) using the Scion Image Release Beta
4.0.2 software program. All densitometric values given in the
present work are related to the anti-phosphotyrosine/anti-ErbB2
signal ratio to correct for possible deviation due to loading errors.
Little, if any, loading error, however, was observed by staining
proteins in the PVDF membranes with Fast Green FCF.
RESULTS
ErbB2 activation in SK-BR-3 cells
We have demonstrated previously that CaM interacts and regulates
the EGFR in vitro [12–15] and in living cells [16]. Therefore it
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Figure 1 HRGβ1 stimulates the phosphorylation of ErbB2 overexpressed
in SK-BR-3 cells
(A) Whole cell extracts (approx. 60 µg of protein) from A431 and SK-BR-3 cells were separately
subjected to SDS/PAGE and Western blot analysis using anti-EGFR (α-EGFR) or anti-ErbB2
(α-ErbB2) antibodies as described in the Experimental section. The arrows point to EGFR or
ErbB2. (B) Whole cell extracts (150 µg of protein) of SK-BR-3 cells from a non-treated culture
(−) or a culture treated (+) with 100 ng/ml HRGβ1 for 5 min were subjected to SDS/PAGE and
Western blot analysis as described in the Experimental section. The PVDF membrane was first
probed with the anti-phosphotyrosine antibody (α-P-Tyr), and thereafter stripped and reprobed
with the anti-ErbB2 antibody (α-ErbB2). The arrows point to ErbB2. Representative results from
two (A) and three (B) separate experiments are presented.
was important to exclude the possibility that this receptor could
interfere with the undertaken studies on the interaction between
CaM and ErbB2, as both receptors have very close molecular
masses (170 kDa for EGFR and 185 kDa for ErbB2). We chose
SK-BR-3 cells for the present study, as this cell line is known
to overexpress ErbB2 while expressing far lower levels of other
ErbB receptors, including the EGFR [26].
To confirm that this was the case in the clone of SK-BR-3 cells
used, we performed Western blot analysis of whole cell extracts
using anti-EGFR and anti-ErbB2 antibodies. Thus Figure 1(A)
shows a weak EGFR signal on SK-BR-3 cells as compared with
control A431 cells, which are known to overexpress this receptor
[27]. In order to observe the weak EGFR signal in SK-BR-3
cells, the X-ray film was slightly overexposed. In contrast, a
strong ErbB2 signal was detected on SK-BR-3 cells, while this
signal was almost absent in A431 cells. This also demonstrates
that the anti-ErbB2 antibody used in our experiments does not
present cross-reactivity towards EGFR. To determine whether
or not ErbB2 was able to undergo activation, we incubated
SK-BR-3 cells in the absence and presence of HRGβ1 and
performed Western blots using an anti-phosphotyrosine antibody.
As shown in Figure 1(B), phosphorylation of tyrosine of ErbB2
was stimulated strongly upon addition of HRGβ1. The samples
were reprobed with an anti-ErbB2 antibody to determine that they
contain comparable amounts of receptor. Densitometric analysis
showed that the mean +− S.E.M. of HRGβ1-induced stimulation
of ErbB2 phosphorylation increased to 641 +− 179% (n = 3) as
measured in whole cell extracts, and to 346 +− 84% (n = 4) as me-
asured in cell membrane fraction preparations.
Figure 2 shows that ErbB2 can be activated by EGF, as
observed by Western blot analysis using an anti-phosphotyrosine
Figure 2 EGF activates ErbB2 while EGFR was undetected on
immunoprecipitated ErbB2 preparations
Whole cell extracts (CE) (120 µg of protein) or immunoprecipitated ErbB2 (IP) from 3.4 mg
cell lysate proteins of SK-BR-3 cells of a non-treated culture (−) or a culture treated (+) with
10 nM EGF for 1 min were subjected to SDS/PAGE and Western blot analysis as described in the
Experimental section. Separate samples were probed with anti-phosphotyrosine (α-P-Tyr), anti-
ErbB2 (α-ErbB2) or anti-EGFR (α-EGFR) antibodies. The arrows point to ErbB2. Representative
results from three (CE) and seven (IP) separate experiments are presented.
antibody. This was observed using both the whole cell extract
and the immunoprecipitated ErbB2 from SK-BR-3 cells. The
stimulation of tyrosine phosphorylation in ErbB2 induced by
EGF was, however, less pronounced than the stimulation induced
by HRGβ1, when the signals in the presence or absence of
either of the two growth factors were compared (see Figure 1B
and Figure 2, top panel). Densitometric analysis shows that the
EGF-induced stimulation of ErbB2 phosphorylation increased
to 179 +− 23% (n = 3) as measured in whole cell extracts, and to
128 +− 3% (n = 6) as measured using the immunoprecipitated
receptor. As expected, ErbB2 was detected in both the whole
cell extract and the immunoprecipitated material when probed
with an anti-ErbB2 antibody (Figure 2, middle panel), while no
EGFR signal was observed when samples where probed with an
anti-EGFR antibody (Figure 2, bottom panel).
To characterize whether or not the activation of ErbB2 from
SK-BR-3 cells generate a proliferative response upon addition
of exogenous HRGβ1 or EGF, we measured the incorporation of
[methyl-3H]thymidine into DNA under different experimental
conditions. Figure 3(A) shows that SK-BR-3 cells incorporate
[methyl-3H]thymidine with great efficiency in the absence of any
added growth factor, and that the addition of 10 nM HRGβ1
or 10 nM EGF, in the absence or presence of 10% (v/v) FBS,
does not stimulate DNA synthesis further. Moreover, increasing
the concentrations of HRGβ1 or EGF also fails to enhance the
incorporation of [methyl-3H]thymidine above its already high
basal level, as observed in Figure 3(B).
ErbB2 binds CaM in a specific and Ca2+-dependent manner
To determined whether or not ErbB2 could be isolated by CaM-
affinity binding, we performed pull-down experiments using
CaM-agarose. Figure 4(A) shows that ErbB2 could be detected
by Western blot analysis using an anti-ErbB2 antibody in the
material bound to the CaM–agarose beads when the experiments
were performed in the presence of CaCl2, but not in its absence
(in the presence of EGTA). Interestingly, in most preparations,
the presence of the CaM inhibitor W7 during the incubation
procedure increased the binding of ErbB2 to the CaM–agarose
c© 2004 Biochemical Society
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Figure 3 Effect of EGF and HRGβ1 on SK-BR-3 cell proliferation
Incorporation of [methyl-3H]thymidine into DNA was performed as described in the Experimental
section. (A) The experiments where performed in the presence of 10 nM EGF, 10 nM HRGβ1
and/or 10 % (v/v) FBS as indicated. Results are means +− S.E.M. of eight determinations in two
separate experiments. (B) The experiments were performed using the indicated concentrations
of EGF () or HRGβ1 (H17009). Results are means +− S.E.M. of six determinations in two separate
experiments. The 100 % value corresponds to 70 000 c.p.m.
beads, most likely because the inactivation of endogenous CaM
that binds and competes for ErbB2. Densitometric analysis
shows that the binding of ErbB2 to CaM–agarose increased to
140 +− 36% (n = 4) in the presence of W7 as compared with
controls in the absence of the CaM antagonist (results not shown).
Furthermore, we isolated ErbB2 by Ca2+-dependent CaM-affinity
chromatography. Thus Figure 4(B) shows the absence of ErbB2
in the CaM–agarose column effluent after an extensive wash with
a buffer containing CaCl2, and the appearance of the receptor
after elution with a buffer containing EGTA, as detected using an
anti-ErbB2 antibody (Figure 4B, upper panel). A negative control
using the secondary anti-IgG antibody alone is also presented
(Figure 4B, lower panel). Overall, these experiments show that
CaM binds to ErbB2 in a Ca2+-dependent manner.
The detection of ErbB2 in the CaM–agarose beads in the pre-
sence of Ca2+, and its elution with EGTA, does not exclude, how-
ever, the possibility that this receptor could be isolated because
of its indirect association with other CaM-binding protein(s).
In fact, many different CaM-binding proteins can be detected in
SK-BR-3 cells after overlaying the electrophoretically separated
proteins with biotinylated CaM as shown in Figure 5. Hence, we
detected CaM-binding proteins in the whole extracts from SK-
BR-3 cells in experiments performed in the presence of CaCl2
(Figure 5, right-hand panel). In its absence (Figure 5, middle
panel), however, the only observed bands were also detected in a
mock experiment carried out in the absence of biotinylated CaM
Figure 4 ErbB2 binds to CaM–agarose
(A) A solubilized whole cell extract (2.8 mg of protein) from non-stimulated SK-BR-3 cells was
subjected to pull-down using CaM–agarose beads as described in the Experimental section
in the presence (+) of 0.2 mM CaCl2 (Ca2+) or 1 mM EGTA as indicated. The material bound to
the beads was subjected to SDS/PAGE and Western blot analysis using the anti-ErbB2 antibody
(α-ErbB2). The arrow points to ErbB2. Representative results from two independent experiments
are presented. (B) A solubilized whole cell extract (25 mg of protein) from non-stimulated
SK-BR-3 cells was subjected to CaM-affinity chromatography as described in the Experimental
section. Pooled fractions after Ca2+-wash and EGTA-elution were subjected to SDS/PAGE and
Western blot analysis using an anti-ErbB2 antibody (α-ErbB2) (upper panel). A control using
only the secondary antibody (α-IgG) is also presented (lower panel) The arrow points to ErbB2.
Representative results from two separate experiments are presented.
Figure 5 Ca2+-dependent CaM-binding proteins in SK-BR-3 cells
A whole cell extract (100 µg of protein) from SK-BR-3 cells of a non-treated culture (−) or a
culture treated (+) with 10 nM EGF for 1 min were subjected to SDS/PAGE, before electrotransfer
of the proteins on to a PVDF membrane, and overlay with 0.45 µg/ml biotinylated CaM in the
presence of 0.2 mM CaCl2 (Ca2+) and in its absence (EGTA) as described in the Experimental
section. Samples were processed in the absence of biotinylated CaM (Control) to detect non-
specific binding. The arrow indicates a broad high-molecular-mass (190–160 kDa) CaM-
binding protein band. Representative results from two independent experiments are presented.
after development with streptavidin–peroxidase (Figure 5, left-
hand panel), showing its non-specific binding. Little change, if
any, in the binding of biotinylated CaM to the different CaM-
binding proteins was observed between cell extracts from non-
stimulated cells and cells stimulated with EGF. Significantly, a
positive broad band of high molecular mass (190–160 kDa), the
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Figure 6 Direct and specific Ca2+-dependent binding of biotinylated CaM
to immunoprecipitated ErbB2
The immunoprecipitated ErbB2 from 2.6 mg of protein cell extract of SK-BR-3 cells of a non-
stimulated culture (−) or a culture stimulated (+) with 10 nM EGF for 1 min, were subjected
to overlay with 0.45 µg/ml biotinylated CaM in the presence of 0.2 mM CaCl2 (Ca2+) and
135 µg/ml free CaM as indicated, and described in the Experimental section. A control in the
absence of CaCl2 and presence of 1 mM EGTA is also presented (EGTA). The PVDF membrane
was sequentially stripped and reprobed with the anti-phosphotyrosine antibody (α-P-Tyr), and
the anti-ErbB2 antibody (α-ErbB2). The arrows point to ErbB2, and the asterisk indicates p160.
Representative results from two separate experiments are presented.
region of migration of ErbB receptors, was detected (Figure 5,
arrow).
To determine whether ErbB2 could be responsible at least in
part for the high-molecular-mass signal observed in overlay ex-
periments with biotinylated CaM using whole cell extracts, we
repeated the experiment using immunoprecipitated ErbB2. Fig-
ure 6 shows that biotinylated CaM binds to a 185 kDa band in
the immunoprecipitated material in the presence of CaCl2 (Fig-
ure 6, Ca2+ lanes), but not in its absence (Figure 6, EGTA lanes).
Moreover, the addition of an excess of free CaM chases the bind-
ing of its biotinylated form to this 185 kDa protein. No signi-
ficant change was observed when non-stimulated cells or cells
stimulated with EGF were used. Moreover, a prominent 160 kDa
Ca2+-dependent CaM-binding protein (p160) co-immunopre-
cipitated with ErbB2 was detected (Figure 6, asterisk). An excess
of free CaM also chases the binding of biotinylated CaM to
p160. When the PVDF membrane was sequentially re-probed with
anti-phosphotyrosine and anti-ErbB2 antibodies, we observed a
perfect match between the biotinylated CaM signal, and the ErbB2
and tyrosine phosphorylation signals of the 185 kDa band. These
experiments, therefore, show that CaM directly and specifically
binds to ErbB2 in a Ca2+-dependent manner.
The CaM antagonist W7 inhibits HRGβ1-induced ErbB2
phosphorylation in intact cells
As mentioned above, the presence of the CaM antagonist W7
increases the binding of ErbB2 to CaM–agarose beads in vitro.
We next decided to test whether or not this compound affects
the activation of ErbB2 in intact cells. Figure 7(A) shows that the
level of HRGβ1-induced phosphorylation of ErbB2 decreases in
cells treated with W7 during 30 min before the addition of the
ligand. The phosphorylation of the receptor was tested in isolated
membrane fractions solubilized with Triton X-100 from HRGβ1-
treated and untreated cells. Although the phosphorylation signal
in the Western blot correlates perfectly with the ErbB2 signal, as
detected using an anti-ErbB2 antibody, to ascertain further that
Figure 7 The CaM antagonist W7 inhibits ErbB2 phosphorylation in intact
cells
(A) Serum-deprived SK-BR-3 cells were treated with 5 µg/ml W7 for 30 min and then stimulated
with 100 ng/ml HRGβ1 for 2 min as indicated. Thereafter, solubilized cell membrane extracts
(100 µg of protein) were prepared and subjected to SDS/PAGE, before electrotransfer of the
proteins on to a PVDF membrane, and Western blot analysis using an anti-phosphotyrosine
antibody (α-P-Tyr) as described in the Experimental section. The PVDF membrane was
subsequently stripped and reprobed with the anti-ErbB2 antibody (α-ErbB2). The arrows point
to ErbB2. (B) Serum-deprived SK-BR-3 cells were treated with 5 µg/ml W7 for 30 min and then
stimulated with 100 ng/ml HRGβ1 for 2 min as indicated. Thereafter, the immunoprecipitated
ErbB2 from 1.3 mg of protein cell extract was subjected to SDS/PAGE, before electrotransfer of
the protein on to a PVDF membrane, and Western blot analysis using an anti-phosphotyrosine
antibody (α-P-Tyr) as described in the Experimental section. The PVDF membrane was
subsequently stripped and reprobed with the anti-ErbB2 antibody (α-ErbB2). The arrows
point to ErbB2. Representative results from five (A) and two (B) independent experiments are
presented.
the observed W7-induced decrease in phosphorylation took
place in ErbB2 and not in any unrelated protein of similar mole-
cular mass, we performed a similar experiment, but using the
immunoprecipitated ErbB2 from HRGβ1-treated and untreated
cells. Thus we observed again that W7 treatment strongly inhi-
bits the HRGβ1-induced phosphorylation of ErbB2 (Figure 7B).
In this instance, however, we also observed a significant W7-
induced inhibition of the basal phosphorylation of ErbB2 in
the absence of HRGβ1. Densitometric measurements show that
treating living cells with 5 µg/ml W7 inhibited HRGβ1-depen-
dent stimulation of ErbB2 phosphorylation to 81 +− 12% (n = 4)
as measured in cell membrane fractions, and to 30 +− 8% (n =
2) as measured using immunoprecipitated ErbB2. In the absence
of HRGβ1, W7 treatment inhibits ErbB2 phosphorylation to 16 +−
1.5% (n = 2) as measured using immunoprecipitated ErbB2.
Furthermore, we observed that W7 treatment also inhibits
HRGβ1-dependent tyrosine phosphorylation of four different
phosphoproteins downstream of ErbB2, most likely protein
substrates of its tyrosine kinase activity, denoted pp130, pp110,
pp60 and pp51 (results not shown).
It has been reported that W7 at very high concentrations
inhibits protein kinase C activity by two mechanisms: interacting
with the phospholipid cofactor of the enzyme (IC50 = 260 µM),
and acting as a competitive inhibitor of ATP (at even higher
concentrations) [28]. Although the concentration of W7 used in
our experiments with living cells was approx. 5–15-fold lower
than the IC50 indicated above, we had to exclude nonetheless the
possibility that W7 could be acting as a non-specific inhibitor of
ErbB receptor tyrosine kinase activity. To this end, we directly
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Figure 8 Naphthalenesulphonamide-derivative CaM antagonists do not act
as non-specific ErbB tyrosine kinase inhibitors
Rat liver purified EGFR (40 µl) was incubated for 15 min on ice in the absence or presence of
15 µg/ml W12, 15 µg/ml W13 or 15 µg/ml W7 as indicated, and thereafter assayed for 2 min at
37 ◦C in 100 µl of a medium containing 15 mM Hepes/NaOH (pH 7.4), 5 mM MgCl2, 0.4 mM
EGTA, 0.5 mM CaCl2 (0.1 mM free Ca2+), 0.1 mg/ml poly(L-Glu/L-Tyr), 1 µM EGF and 10 µM
[γ -32P]ATP (2 µCi). The reaction was arrested upon addition of 10 % (w/v) trichloroacetic acid,
and the precipitated proteins were processed by SDS/PAGE and autoradiography as indicated
in the Experimental section. Results are means +− range of the densitometric intensities of
the autophosphorylated 170 kDa EGFR band (grey bars) and the phosphorylated exogenous
substrate poly(L-Glu/L-Tyr) (black bars) for two independent experiments, considering 100 % to
be the values obtained in the absence of CaM antagonists.
assayed W7, and the related compounds W13 [N-(4-amino-
butyl)-5-chloro-1-naphthalenesulphonamide] and W12 [N-(4-
aminobutyl)-1-naphthalenesulphonamide], on the tyrosine kinase
activity of an isolated preparation of EGFR, as ErbB2 cannot be
assayed by itself in an isolated system. As shown in Figure 8,
neither of these CaM antagonists, which have different inhibitory
capacity for this protein (W7 > W13  W12), were able to inhibit
either the auto(trans)phosphorylation of the receptor (Figure 8,
grey bars), or its tyrosine kinase activity toward the exogenous
substrate poly(L-Glu/L-Tyr) (Figure 8, black bars) at identical or
3-fold higher concentrations than the ones used in our experiments
in living cells. On the contrary, W7 and W13, the most efficient
CaM antagonists, significantly increased the tyrosine kinase
activity of EGFR toward the substrate poly(L-Glu/L-Tyr). These
results were expected, as these CaM antagonists could possibly
inactivate endogenous CaM present in the EGFR preparations,
which may partially inhibit the receptor tyrosine kinase activity
as reported previously [12,13]. Furthermore, we have shown pre-
viously that treating living cells with these CaM antagonists also
prevents the full activation of EGFR [16] in a similar fashion as
observed with the activation of ErbB2 (this work).
Diverse actions of W7 on signalling pathways downstream of ErbB2
To test the possible involvement of CaM on signalling pathways
downstream of ErbB2, we focused our attention on the activation
status of different MAPK pathways (ERK, p38 MAPK and
JNK), the PI3K (phosphoinositide 3-kinase)/Akt pathway and the
activity of several ErbB2-activated Ca2+-dependent transcription
factors [CREB, ATF1 and NFAT (nuclear factor of activated
T-cells)] in the absence and presence of HRGβ1 and/or the
CaM antagonist W7. Figure 9 shows that, concomitant with
the inhibitory action of W7 on the HRGβ1-dependent tyrosine
phosphorylation of ErbB2, (Figure 9, α-P-Tyr panel), the CaM
antagonist also induces the down-regulation of the Ras/MAPK
Figure 9 Effect of W7 on downstream ErbB2 signalling pathways
Serum-deprived SK-BR-3 cells were incubated in the absence (−) and presence (+) of 15 µg/ml
W7 for 30 min, and then stimulated with 10 nM HRGβ1 for 2 min as indicated. Thereafter,
whole cell extracts (60 µg of protein) were prepared and subjected to SDS/PAGE. The proteins
were electrotransferred on to a PVDF membrane, and different Western blot analyses were
performed using anti-phosphotyrosine (α-P-Tyr), anti-ErbB2 (α-ErbB2), anti-phospho-ERK1/2
(α-P-ERK1/2), anti-phospho-Akt/PKB (α-P-Akt/PKB) and anti-phospho-CREB (α-P-CREB)
(also recognizing phospho-ATF1, P-ATF1) antibodies as described in the Experimental section.
The ErbB2 signal (α-ErbB2) constitutes one of the multiple loading controls performed (see the
Experimental section) corresponding to the stripped and reprobed PVDF membrane presented
in the α-P-Tyr panel. Representative results from six (α-P-Tyr), six (α-ErbB2), five (α-P-
ERK1/2), five (α-P-Akt/PKB) and five (α-P-CREB) independent experiments performed in
identical or similar conditions (5–20 µg/ml W7) are presented. Arrows point, respectively,
to phosphorylated ErbB2 (α-P-Tyr), total ErbB2 (α-ErbB2), phosphorylated ERK1/2 (top and
bottom arrows) (α-P-ERK1/2), phosphorylated Akt/PKB (α-P-Akt/PKB), and phosphorylated
CREB (top arrow) and ATF1 (bottom arrow) (α-P-CREB/P-ATF1).
(ERK) and PI3K/Akt pathways, as shown determining the levels
of phospho-ERK1/2 (Figure 9, α-P-ERK1/2 panel) and phospho-
Akt/PKB (Figure 9, α-P-Akt/PKB panel) respectively. Little,
if any, activation of the p38 MAPK and JNK pathways was
observed upon W7 treatment, as determining the phosphorylated
(active) forms of p38 MAPK and JNK (results not shown). In con-
trast, we observed that W7 induces a significant increase in the
phosphorylation status of the Ca2+-dependent transcription fac-
tors CREB (Figure 9, α-P-CREB/P-ATF1 panel, upper band) and
ATF1 (Figure 9, α-P-CREB/P-ATF1 panel, lower band) as deter-
mined using an anti-phospho-CREB/anti-phospho-ATF1 anti-
body. Significantly, the activation levels of both the Akt/PKB
pathway, and the transcription factors CREB and ATF1, were
already very high under basal conditions (absence of HRGβ1) in
SK-BR-3 cells. Preliminary results show that the Ca2+-dependent
transcription factor NFAT is localized in the nuclear fraction of
non-stimulated (absence of HRGβ1) SK-BR-3 cells, which makes
it difficult to evaluate the potential effect of W7 in the cytosol-to-
nucleus translocation process (results not shown).
DISCUSSION
In the present report, we have extended our studies on the inter-
action of CaM with tyrosine kinase receptors of the EGFR family
to ErbB2. Hence, we have shown that CaM binds specifically and
directly to ErbB2 in a Ca2+-dependent manner. The functional
activation of ErbB2 by HRGβ1 or EGF obligatorily requires
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its heterodimerization with another ErbB receptor partner. The
human breast adenocarcinoma SK-BR-3 cells used in the present
study overexpress ErbB2, and express limited amounts of EGFR,
ErbB3 and ErbB4 [26], sufficient, however, to warrant the
activation of ErbB2 upon ligand stimulation, either by HRGβ1 or
EGF. Since we had demonstrated previously that EGFR interacts
directly with CaM in a specific Ca2+-dependent manner [12–
16], it was important to exclude the possibility that this receptor
was interfering with the observed interaction between CaM and
ErbB2. Our results clearly demonstrate that the low level of
EGFR expression in this cell line, although it may be required
for ErbB2 activation, was not interfering, as the immunopreci-
pitated ErbB2 preparations used in this study were free of EGFR.
We also observed that the activation of ErbB2 does not appear to
significantly modify the binding of CaM to this receptor, similarly
to what we had previously shown with the binding of CaM to
EGFR [15,16].
When we used immunoprecipitated ErbB2, in addition to de-
monstrating that the Ca2+–CaM complex binds directly and spe-
cifically to this receptor, we showed that these preparations
contain an additional 160 kDa CaM-binding protein (p160), sug-
gesting that this protein co-immunoprecipitated with ErbB2.
Interestingly, we have shown previously that two CaM-binding
proteins (p190 and p160) co-immunoprecipitated with EGFR
from two different cell lines tested [15]. The nature and function
of these CaM-dependent proteins are unknown, although it is
tempting to speculate that the p160 that co-immunoprecipitated
with both ErbB2 and EGFR is the same protein.
The high level of [methyl-3H]thymidine incorporation into
DNA in these cells in the absence of added growth factors, and the
absence of stimulation of this basal incorporation level upon ad-
dition of exogenous HRGβ1 or EGF, suggest the production by
these cells of endogenous ErbB ligand(s) able to induce autocrine/
paracrine stimulation, and/or that the activated ErbB2 may addi-
tionally intervene in non-proliferative pathways, for example in
cell migration, as already demonstrated [29]. Therefore the po-
tential functional role that CaM may have in modulating ErbB2
activity could encompass not only the regulation of cell prolife-
ration, but perhaps additional functions mediated by this receptor
such as the modulation of cell motility. Because ErbB2 cannot
form functional homodimers [1,2,5,6], it was not possible to test
the effect of CaM on the tyrosine kinase activity of an isolated
preparation of this receptor directly, in contrast with the case
of EGFR where we indeed demonstrated that CaM inhibits its
tyrosine kinase activity [12,13]. Therefore indirect approaches
should be employed to obtain some clues about the possible action
of CaM on the functionality of ErbB2. A logical option was to use
a cell-permeant CaM antagonist in intact living cells to determine
its action on ErbB2 activation. To this end we used the CaM
antagonist W7 [30].
When we tested W7 in vitro, we observed that this compound
does not prevent the Ca2+-dependent association of ErbB2 to
CaM–agarose. On the contrary, we observed an increase binding
of ErbB2. This suggests that the region of CaM involved in the
interaction with ErbB2 is not affected by the conformational
change of CaM induced by this inhibitor, and that the inhibition
of endogenous CaM, possibly present in the preparation, favours
the binding of ErbB2 to the immobilized CaM. This does not
exclude, however, that the CaM–W7 complex was incompetent
in blocking a regulatory response of CaM on ErbB2. In fact, our
results show that treating intact living cells with W7 significantly
diminishes the HRGβ1-dependent phosphorylation of ErbB2.
Similarly, we have observed in other cell lines that overexpress
EGFR that W7, and a related CaM antagonist (W13), inhibit
the EGF-dependent phosphorylation of EGFR in vivo [16]. More-
over, W7 has been shown to inhibit EGF-induced, but not EGF-
independent, proliferation of a human hepatoma cell line [31].
The use of W7 in intact cells, where we observed the down-
regulation of ErbB2 tyrosine phosphorylation, made it mandatory
to test that this CaM antagonist does not act as a non-specific
ATP-binding-site kinase inhibitor, as it has been shown for protein
kinase C, albeit at extremely high concentrations [28]. We tested
directly, not only W7, but also W13 and W12, other members
of this family of CaM antagonists with different inhibitory
potentials (W7 > W13  W12), on the tyrosine kinase activity of
isolated EGFR. Our results show conclusively that none of these
compounds inhibit the EGF-induced auto(trans)phosphorylation
of the receptor nor the tyrosine kinase activity toward an exoge-
nous substrate. Therefore we conclude that the observed effect
of W7 on living cells on ErbB2 (in the present study) and EGFR
[16] is not due to any artifactual inhibition of the receptor tyrosine
kinase activity.
We also noticed that treatment of cells with W7 in the absence of
HRGβ1 induced a decrease in the basal phosphorylation of ErbB2
as detected after immunoprecipitation of the receptor, but this
inhibition was not detected after isolation of ErbB2 from deter-
gent-solubilized membranes. The reason could be the existence
of different pools of ErbB2 within different cell membranes, as
we have detected a Triton X-100-insoluble membrane pool con-
taining high levels of phosphorylated ErbB2, which appears not
to be affected by W7 treatment (results not shown).
How the inhibition of CaM by W7 in intact cells mediates the
inactivation of ErbB2 is not yet known. The indirect inhibition
of CaM-dependent kinases, such as CaMK-II and CaMK-IV, was
considered. This, however, is very unlikely, as the phosphorylation
of ErbB2 at Thr1172 by CaMK-II has been documented, and the
mutation of this phosphorylation site produces a defect in the de-
sensitization of an ErbB2–EGFR chimaera and a more sustained
EGF-induced phosphorylation of this receptor as compared with
a non-mutated chimaeric receptor [32]. These observations,
therefore, do not support the idea that failure in phosphorylation of
ErbB2 by CaMK-II could be responsible for our findings because
W7 treatment induced receptor down-regulation, not receptor up-
regulation.
Consequently, some other possibilities were considered.
Among these, several conceivable options should be mentioned:
(i) that the inhibition of intracellular CaM could facilitate
ErbB2 dephosphorylation by activation of a phosphatase down-
regulated by CaM; (ii) that inhibition of CaM could increase
the internalization of ErbB2, preventing in this manner access
to extracellular HRGβ1; and (iii) that CaM inhibition could
induce a redistribution of ErbB2 between different intracellular
compartments, as we have noticed the presence of a conspicuous
ErbB2 pool resistant to Triton X-100 solubilization in SK-BR-3
cells (results not shown). In this context, although several protein
tyrosine phosphatases have been shown to dephosphorylate ErbB2
[33–35], we are not aware, however, that these dephosphorylation
pathways are under the control of CaM. In contrast, with respect
to ErbB2 internalization, there is the precedent that CaM has been
shown to be involved in the intracellular trafficking of EGFR, a
related receptor of the same family, as the treatment of living cells
with the CaM antagonist W13 induces the sequestration of this
receptor in endosomes [36]. Therefore it is likely that ErbB2 could
behave in the same manner. Notwithstanding the uncertainties
about the mechanism of action of W7 on the decreased phospho-
rylation of ErbB2, our results show clearly that CaM plays a direct
or indirect role on the regulation of the activity or ErbB2 in intact
cells.
Furthermore, we tested the effect of W7 on ErbB2-initiated
downstream signalling pathways in living cells. As expected, the
c© 2004 Biochemical Society
ErbB2/Neu/HER2 binds calmodulin 265
Ras/MAPK (ERK), and PI3K/Akt pathways were both inhibited
concomitant with ErbB2 down-regulation. These inhibitory
actions should not, however, be ascribed exclusively to a decrease
in ErbB2 signalling capacity, as CaM is known to regulate several
steps of the Ras/MAPK (ERK) pathway directly [37]. Thus W13, a
related CaM antagonist, has been shown to inhibit the Ras/MAPK
(ERK) pathway to the level of Raf-1, a kinase upstream of ERK1/2
[36]. Nevertheless, the action of CaM on the Ras/MAPK (ERK)
pathway appears to be very complex, as in some cell types, it
has been shown that CaM blockade by W13 induces a sustained
activation of this signalling route at the level of Ras, Raf and MEK
[38].
An increase in [Ca2+]cyt is known to control, with the interven-
tion of CaM, the function of several Ca2+-responsive transcription
factors such as CREB [39–42], ATF1 [43] and NFAT [44,45],
among others. We have shown that the treatment of living cells
with W7 elicits the up-regulation of CREB and ATF1. These
results support the notion that W7 is indeed inactivating CaM,
subsequently inducing a failure in calcineurin activity, and thereby
an increase in the phosphorylation level of CREB and ATF1, as
expected [40]. This is despite the fact that CREB appears to be in
part phosphorylated by CaMK-II and CaMK-IV [39,41].
Overall, these results show that CaM is not only acting in living
cells on the ErbB2 receptor itself, but also at different points of
ErbB2-initiated downstream signalling pathways, such as the Ras/
MAPK (ERK) and PI3K/Akt pathways, and their gene transcri-
ptional activity mediated by downstream Ca2+-dependent trans-
cription factors.
As mentioned above, the sequence similarity of the CaM-BD of
EGFR with homologous regions of other ErbB receptors is very
high. Thus we have postulated that ErbB2 could interact with
CaM at its cytosolic juxtamembrane region, and that additional
members of this family of tyrosine kinase receptors, ErbB3 and
ErbB4, particularly the latter, could also be CaM-binding proteins
[11,14]. Further work should be carried out to demonstrate if this
is indeed the case.
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